Navigation Links
Contract Research Organization WCCT Global Welcomes Edward Kim as Executive Director, Early Clinical Development
Date:11/5/2013

Costa Mesa, Ca (PRWEB) November 05, 2013

WCCT Global (WCCTG) is pleased to announce and welcome Mr. Edward Kim as Executive Director, Early Clinical Development. Ed will be overseeing the WCCTG, Cypress and Costa Mesa Clinical Pharmacology Research Units. As a Contract Research Organization professional Mr. Kim has over 17 years of Early Phase clinical research experience in both academia and the site/CRO industry. Nearly 15 years of his career was with California Clinical Trials/Parexel International, where he served as Director of Clinical Operations. He was responsible for managing all clinical operations (Clinical Research Teams, Pharmacy, Laboratory, and Nursing) for their expanded 100+ beds across their 3 Phase I units. Mr. Kim has conducted over 400 clinical trials supporting CNS indications, Asian ethnobridging, “CSF-dynabridging” programs, and various specialized programs in healthy normal populations. When asked how Ed felt to be joining WCCT Global, he replied, “I am extremely excited to be joining this dynamic and growing organization, and look forward to leveraging my background and knowledge in this space to help WCCTG continue to grow.”

“This is another great addition to WCCT Global,” exclaimed Jon Rojas, WCCTG’s Chief Operating Officer, “because this service offering is part of WCCTG’s core business which continues to grow. Having team members like Mr. Kim is why we are contacted by sponsors all over the world to perform clinical studies in many different therapeutic areas.”

More about WCCT Global:
WCCT Global is a multi-site, full service global contract research organization (CRO) of outsourced early drug development and late phase services to the pharmaceutical, biotechnology and medical device industries. The WCCT Global vision, “With compassion for people, we strive for tomorrow’s therapies to be available today” truly exemplifies the focus and reason for our cutting edge work both in our clinics and throughout our operations. As a drug development partner, WCCT Global collaborates with domestic and foreign innovator companies who need regulatory, program management, data management and strategic consulting support, with an emphasis on overseeing and executing trials in special disease populations, pediatric populations, ethno-bridging, and cardiac safety. WCCT has extensive experience with healthy volunteer studies including First-in-Human (FIH), as well as specific therapeutic expertise in Allergy, Asthma, HCV, Ophthalmology, Oncology, Renal, and Vaccines.

If you would like to request information how WCCT Global can assist your organization with your next clinical study, click here.

Read the full story at http://www.prweb.com/releases/2013/11/prweb11300059.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Arizona State University secures defense contract
2. Actos Bladder Cancer Lawsuit Filed in Louisiana Alleging Woman Used Diabetes Medication and Contracted Bladder Cancer, Consumer Justice Foundation Reports
3. Local Woodinville Contractor, Washington State Kitchen and Bath, Combats Toxic Mold, Adhering to the Toughest Mold Protection Standards in the Nation with New Promotion
4. Collagenase for Dupuytrens contracture: Added benefit not proven
5. BMC awarded contract to study validity of primary care drug screening tools
6. Federal government renews contract for collecting and maintaining national stem cell transplantation database
7. NIH awards Georgia malaria research consortium up to $19.4 million contract
8. Care2Learn/Upstairs Solutions and Jarlette Health Services Sign Multi-Year Contract for Online Training and Record-Keeping
9. NHS consultant contract fails to increase productivity
10. PLEXERA® LLC Launches Contract Research Services Business for Biomolecular Interaction Studies
11. Securityhunter, Inc. Selected as a Top 25 Baltimore Defense Contractor for the Baltimore Business Journal's 2013 Book of Lists
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 26, 2016 , ... ... have been diagnosed with endometriosis. These women need a treatment plan to not ... comprehensive approach that can help for preservation of fertility and ultimately achieving a ...
(Date:6/25/2016)... Miami, FL (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton ... Plant City Observer , brings up a new, often overlooked aspect of head lice: ... The closing for fumigation is not a common occurrence, but a necessary one in the ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar ... M.D from the David Geffen School of Medicine at UCLA. He trained in Internal ... complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the ... In terms of the latter, setting the bar too high can result in disappointment, ... just slow progress toward their goal. , Research from PsychTests.com reveals ...
(Date:6/24/2016)... ... 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. In ... benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued ... Sickle Cell Disease (SCD) is a disorder of the red blood cells, which can ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)...  MedSource announced today that it has selected ... of choice.  This latest decision demonstrates MedSource,s commitment ... clients by offering a state-of-the-art electronic data capture ... as the EDC platform of choice in exchange ... has long been a preferred EDC platform by ...
(Date:6/23/2016)... 2016  In a startling report released today, National Safety ... lacking a comprehensive, proven plan to eliminate prescription opioid overdoses. ... how states are tackling the worst drug crisis in recorded U.S. ... Kentucky , New Mexico , ... Of the 28 failing states, three – Michigan ...
(Date:6/23/2016)... -- Research and Markets has announced the addition ... to their offering. The ... commercial environment for MedImmune to enter. The US ageing population ... to drive considerable growth for effective anti-influenza medications. The introduction ... considerably, but development is still in its infancy. ...
Breaking Medicine Technology: